Yesenia Rivas Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Flagler Dr, Miami Springs, FL 33166 Phone: 786-357-5512 |
Mr. Charles Paul Taffinder, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 517 Wren Ave, Miami Springs, FL 33166 Phone: 305-450-2464 |
Mrs. Omayda G. De La Cruz, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 871 Swan Ave, Miami Springs, FL 33166 Phone: 305-885-5675 |
Laura Pazos-cejas Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 691 Morningside Dr, Miami Springs, FL 33166 Phone: 786-269-6393 |
Jill Theresa Flingos, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1160 Heron Ave, Miami Springs, FL 33166 Phone: 305-512-5757 Fax: 305-512-5757 |
News Archive
Melbourne researchers have revealed the critical importance of highly specialised immune cells, called natural killer cells, in killing melanoma cells that have spread to the lungs.
The American Diabetes Association issues the following statement about the passing of HR 3590 The Patient Protection and Affordable Care Act.
When it comes to stroke rehabilitation, it takes a dedicated team to help a person regain as much independence as possible: physicians, nurses, physiotherapists, occupational therapists, speech-language pathologists, recreation therapists, caregivers and others. Now, a University of Calgary research team has added a robot to help identify and customize post-stroke therapy.
Because the spine is made up of repeating elements that look alike, surgeons can mistakenly operate on the wrong vertebra. To avoid this, Johns Hopkins researchers have developed a software program that works seamlessly with currently available procedures to assist a surgeon's determination of which vertebra is which. Results from its first clinical evaluation show that the LevelCheck software achieves 100 percent accuracy in just 26 seconds.
Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).
› Verified 3 days ago